News Flash

Lot Recalled for Methylin Chewable Tablets

Alliant Pharmaceuticals, Inc. announced it is voluntarily recalling one lot of Methylphenidate HCl Chewable Tablets, 5 mg strength, lot number #AMT50402A. After testing and evaluation, Alliant found that this lot of 5 mg strength might contain up to three times the active ingredient, which could pose a serious health risk for some patients. Alliant estimates that fewer than 500 bottles of the 2,820 bottles from this lot are in distribution.

The affected lot was in production between August 9, 2004 and January 18, 2005. All CareFirst and CareFirst BlueChoice members who filled a prescription for Methylphenidate HCl Chewable Tablets (Methylin® CT) during this time have been notified by Caremark via mail and/or by phone. All physicians who have prescribed this medication have been notified as well.

Methylin® CT is a therapy for Attention Deficit Hyperactivity Disorder and Narcolepsy. To date, Alliant has not received any complaints or reports of adverse events associated with the affected lot.

Members should call their pharmacist or physician if they have questions about the recall. If you wish to report adverse events, please contact Chris LaFreniere, Alliant Pharmaceuticals at 770-817-4500.